Drugs / Reh-acteoside
last change Nov 2016 re-read 2 minutes ago

Reh-acteoside

Developed for
IgA glomerulonephritis
Investigated by
Sun Yat-sen University

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02662283 May → Nov 2016 IgA glomerulonephritis Sun Yat-sen University Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Reh-acteoside ClinicalTrials.gov intervention name — accepted as the source's own label NCT02662283
Route Oral Oral take reh-acteoside (0.4g bid) for 8 weeks” NCT02662283